Wexler RR - Search Results

1

Neutral macrocyclic factor VIIa inhibitors.

Wurtz NR, Parkhurst BL, DeLucca I, Glunz PW, Jiang W, Zhang X, Cheney DL, Bozarth JM, Rendina AR, Wei A, Harper T, Luettgen JM, Wu Y, Wong PC, Seiffert DA, Wexler RR, Priestley ES. Wurtz NR, et al. Among authors: wexler rr. Bioorg Med Chem Lett. 2017 Jun 15;27(12):2650-2654. doi: 10.1016/j.bmcl.2017.04.008. Epub 2017 Apr 19. Bioorg Med Chem Lett. 2017. PMID: 28460818

2

Balanced AT1/AT2 receptor antagonists. 4. XR510 and related 5-(3-amidopropanoyl)imidazoles possessing equal affinity for the AT1 and AT2 receptors.

Quan ML, Chiu AT, Ellis CD, Wong PC, Wexler RR, Timmermans PB. Quan ML, et al. Among authors: wexler rr. J Med Chem. 1995 Jul 21;38(15):2938-45. doi: 10.1021/jm00015a016. J Med Chem. 1995. PMID: 7636854

3

Discovery of losartan, the first angiotensin II receptor antagonist.

Timmermans PB, Duncia JV, Carini DJ, Chiu AT, Wong PC, Wexler RR, Smith RD. Timmermans PB, et al. Among authors: wexler rr. J Hum Hypertens. 1995 Nov;9 Suppl 5:S3-18. J Hum Hypertens. 1995. PMID: 8583479 Review.

4

Preparation of meta-amidino-N,N-disubstituted anilines as potent inhibitors of coagulation factor Xa.

Fevig JM, Cacciola J, Alexander RS, Knabb RM, Lam GN, Wong PC, Wexler RR. Fevig JM, et al. Among authors: wexler rr. Bioorg Med Chem Lett. 1998 Nov 17;8(22):3143-8. doi: 10.1016/s0960-894x(98)00574-5. Bioorg Med Chem Lett. 1998. PMID: 9873692

5

Design and synthesis of potent and selective 5,6-fused heterocyclic thrombin inhibitors.

Dominguez C, Duffy DE, Han Q, Alexander RS, Galemmo RA Jr, Park JM, Wong PC, Amparo EC, Knabb RM, Luettgen J, Wexler RR. Dominguez C, et al. Among authors: wexler rr. Bioorg Med Chem Lett. 1999 Apr 5;9(7):925-30. doi: 10.1016/s0960-894x(99)00113-4. Bioorg Med Chem Lett. 1999. PMID: 10230612

6

Preparation of pyrrolidine and isoxazolidine benzamidines as potent inhibitors of coagulation factor Xa.

Fevig JM, Buriak J Jr, Stouten PF, Knabb RM, Lam GN, Wong PC, Wexler RR. Fevig JM, et al. Among authors: wexler rr. Bioorg Med Chem Lett. 1999 Apr 19;9(8):1195-200. doi: 10.1016/s0960-894x(99)00164-x. Bioorg Med Chem Lett. 1999. PMID: 10328312

7

Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 1.

Quan ML, Liauw AY, Ellis CD, Pruitt JR, Carini DJ, Bostrom LL, Huang PP, Harrison K, Knabb RM, Thoolen MJ, Wong PC, Wexler RR. Quan ML, et al. Among authors: wexler rr. J Med Chem. 1999 Jul 29;42(15):2752-9. doi: 10.1021/jm980405i. J Med Chem. 1999. PMID: 10425086

8

Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2.

Quan ML, Ellis CD, Liauw AY, Alexander RS, Knabb RM, Lam G, Wright MR, Wong PC, Wexler RR. Quan ML, et al. Among authors: wexler rr. J Med Chem. 1999 Jul 29;42(15):2760-73. doi: 10.1021/jm980406a. J Med Chem. 1999. PMID: 10425087

9

Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics.

Wong PC, Quan ML, Crain EJ, Watson CA, Wexler RR, Knabb RM. Wong PC, et al. Among authors: wexler rr. J Pharmacol Exp Ther. 2000 Jan;292(1):351-7. J Pharmacol Exp Ther. 2000. PMID: 10604970

10

The de novo design and synthesis of cyclic urea inhibitors of factor Xa: optimization of the S4 ligand.

Galemmo RA Jr, Wells BL, Rossi KA, Alexander RS, Dominguez C, Maduskuie TP, Stouten PF, Wright MR, Aungst BJ, Wong PC, Knabb RM, Wexler RR. Galemmo RA Jr, et al. Among authors: wexler rr. Bioorg Med Chem Lett. 2000 Feb 7;10(3):301-4. doi: 10.1016/s0960-894x(99)00688-5. Bioorg Med Chem Lett. 2000. PMID: 10698459

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

196 results

Search Page

Filters